预约演示
更新于：2025-04-14
Perflutren lipid microsphere
全氟丙烷脂质微球
更新于：2025-04-14
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-07-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C3F8 |
InChIKeyQYSGYZVSCZSLHT-UHFFFAOYSA-N |
CAS号76-19-7 |
关联
66
项与 全氟丙烷脂质微球 相关的临床试验NCT06066723
A Cross-sectional Pilot Study of 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
NCT06797193
Invoking Subharmonics and Subharmonic Aided Pressure Estimation (SHAPE) for Identifying Portal Hypertension
NCT06185972
Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Locally Advanced Breast Cancer-Phase II
100 项与 全氟丙烷脂质微球 相关的临床结果
登录后查看更多信息
100 项与 全氟丙烷脂质微球 相关的转化医学
登录后查看更多信息
100 项与 全氟丙烷脂质微球 相关的专利（医药）
登录后查看更多信息
2,301
项与 全氟丙烷脂质微球 相关的文献（医药）2025-06-01FLUID PHASE EQUILIBRIA
Accurate calculation and reliable prediction of second virial coefficients for nonpolar mixtures
作者: Qin, Kang ; Xu, Liu ; Duan, Yuan-Yuan
The virial equation of state has a theor. advantage in the calculations of mixturesThe second mixture virial coefficients are with the theor. rigid mixing rules and composed of the second virial coefficients for pure fluids and the cross second virial coefficientsBased on the generalized corresponding state principle second virial coefficient model for pure fluids we proposed before, the generalized cross second virial coefficient models were established with three characteristic parameters for nonpolar binaries in this work.The calculation of the mixture critical temperature requires the binary interaction coefficients (kij).The mixture acentric factor was determined by the arithmetic mean.The mixture critical pressure could be calculated without the critical sp. volumeFor the most sensitive mixing rule of the mixture critical temperature, the kij was optimized for 145 nonpolar binaries.An easily accessible characteristic correlating parameter, the reduced diameter, was proposed to develop the predictive kij correlations for common nonpolar binaries.Due to the complex intermol. interactions between two different mols., the kij correlations were proposed resp. for alkane/alkane binaries, nonpolar binaries containing fluorocarbon, nonpolar binaries containing nitrogen or oxygen, nonpolar binaries containing simple fluids, nonpolar binaries containing carbon dioxide and nonpolar binaries containing neon.Our work was validated to perform satisfactorily from the comparison with the Chueh-Prausnitz kij correlation, Fender-Halsey kij correlation, and Meng kij correlation.Together with our previous work, this work could accurately calculate and reliably predict the second virial coefficients for common nonpolar mixtures
2025-03-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Colour Doppler and Contrast-Enhanced Ultrasound Characteristics in Degenerative Retinoschisis and Retinal Detachment
Article
作者: Macri, Carmelo ; Gun, Meegan ; Sammouh, Fady ; Chan, Weng Onn ; Lee, Yong Min ; Paris, Jai ; Le, Matthew ; Lim, WanYin
PURPOSE:
To investigate and compare the characteristics of colour Doppler ultrasound (CDUS) and contrast-enhanced ultrasound (CEUS) in degenerative retinoschisis (RS) and rhegmatogenous retinal detachment (RD) .
DESIGN:
Prospective, observational case series METHODS: We prospectively enrolled patients with degenerative RS, acute RD, or chronic RD at two tertiary centres from January 2024 to January 2025. Patients underwent clinical examination, ultrawide field photography and optical coherence tomography (OCT) , and CDUS, followed by CEUS with Definity® microbubbles. Ultrasound characteristics between groups were compared.
RESULTS:
We included 65 eyes from 47 patients (25 male, median age 61.8) . There were 51 eyes with RS, 6 eyes with acute RD, and 6 eyes with chronic RD. CDUS revealed no pre-contrast doppler flow in any RS, while all acute RD cases demonstrated doppler flow. CEUS displayed mild microbubble uptake in 18 RS cases (median bubble count of 2) , whereas all RD cases exhibited florid uptake (median bubble count of 48.2) . Compared to RS, acute RD cavities had significantly higher elevation from sclera (by 6.0 CI 2.8 - 9.2 mm) , longer cavity lengths (by 9.8 CI 7.2 - 12.5) , and greater membrane thickness (by 0.89 CI 0.6 - 1.2 mm) . Chronic RD were significantly thicker than RS membranes (by 0.40 CI 0.2 - 0.6 mm) but were no longer or with greater elevation. Pixelated image analysis showed compared to RS, acute RD showed a higher average total particle count (by 45.83 units) , larger particle size (by 66.3 pixels) , and greater total particle area (by 3138 pixels) . Chronic RD cases had mixed CDUS and CEUS findings.
CONCLUSIONS:
CDUS features differentiating between degenerative RS and RD included the lack of doppler flow in RS, higher and longer cavities in acute RD, and thicker membranes in acute and chronic RD. CEUS features differentiating RS and RD included florid microbubble contrast enhancement in acute RD. These findings could aid in the investigation of cases with diagnostic uncertainty.
2025-03-01AMERICAN JOURNAL OF CARDIOLOGY
Illuminating the Safety of Ultrasound Contrast Agents
作者: Strom, Jordan B ; Porter, Thomas R ; Mulvagh, Sharon L ; Main, Michael L ; Grayburn, Paul A
Echocardiography is an essential element for accurate and timely diagnosis of cardiac pathology. In this context, ultrasound enhancing agents (UEAs), are often essential for visualizing endocardial borders,1 evaluating myocardial perfusion, characterizing intracardiac masses, and other applications. Although UEAs have been shown to be safe, rare serious adverse events (SAEs) have been reported. It is in this context that De La Fuente Gonzalez et al performed a systematic review evaluating randomized and observational data comparing the safety of UEA brands from 2018-2023. The authors conclude that "Optison reduces risk of serious adverse events vs. Definity/Lumason." However, the data presented do not support such a conclusion, as will be discussed in this editorial. What can be concluded is that UEAs as a class are extremely safe with very rare SAEs. The use of UEAs during echocardiography are encouraged per guideline-directed indications based upon evidence-based reduction of misdiagnosis and duplicative testing.
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏病 | 中国 | 2022-11-15 | |
| 造影剂 | 美国 | 2001-07-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性劳累性骨筋膜室综合征 | 临床3期 | 美国 | 2020-07-01 | |
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肾脏疾病 | 临床3期 | 中国 | 2017-11-10 | |
| 肾细胞癌 | 临床3期 | 中国 | 2017-11-10 | |
| 肾细胞癌 | 临床3期 | 中国 | 2017-11-10 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 肝病 | 临床3期 | 中国 | 2017-09-21 | |
| 肝细胞癌 | 临床3期 | 美国 | 2016-04-01 | |
| 心脏衰竭 | 临床2期 | 美国 | 2017-06-01 | |
| 子宫附件疾病 | 临床1期 | 美国 | 2017-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 36 | NH002 (Cohort 1) | 膚構淵襯願襯鑰齋淵艱(顧夢鬱鹹願範夢醖壓顧) = 衊選觸夢繭壓鑰鑰範壓 壓艱鏇鬱鏇鬱獵獵艱鑰 (糧網糧選選夢獵簾積觸, 19.37) 更多 | - | 2024-12-20 | ||
NH002 (Cohort 2) | 膚構淵襯願襯鑰齋淵艱(顧夢鬱鹹願範夢醖壓顧) = 壓鏇膚製築餘鹹衊鬱鏇 壓艱鏇鬱鏇鬱獵獵艱鑰 (糧網糧選選夢獵簾積觸, 24.07) 更多 | ||||||
临床2/3期 | 56 | Intravitreal Tissue Plasminogen Activator (TPA) | 簾製鬱窪繭鹹膚構襯範(繭鹽餘糧繭襯觸廠鹹簾) = 遞築醖製膚憲顧構選醖 網憲選積鏇夢鹹鏇鬱製 (簾鏇鹹艱糧範衊蓋夢選 ) | 积极 | 2024-12-01 | ||
Perfluoropropane (C3F8) | 簾製鬱窪繭鹹膚構襯範(繭鹽餘糧繭襯觸廠鹹簾) = 積簾鬱淵構憲積築觸製 網憲選積鏇夢鹹鏇鬱製 (簾鏇鹹艱糧範衊蓋夢選 ) | ||||||
临床2/3期 | 56 | 鬱蓋願築餘淵顧顧鑰積(願窪觸膚夢製蓋窪簾壓) = 構廠鏇觸範遞齋繭艱觸 願夢糧繭構觸夢糧獵簾 (簾廠願顧網觸淵築壓壓 ) | 积极 | 2024-09-19 | |||
TPA | 鬱蓋願築餘淵顧顧鑰積(願窪觸膚夢製蓋窪簾壓) = 憲餘廠構壓構鹹壓鬱遞 願夢糧繭構觸夢糧獵簾 (簾廠願顧網觸淵築壓壓 ) | ||||||
N/A | 6 | 鹹糧鹽膚淵鑰餘選積膚 = 廠糧壓願積網蓋鹹襯鹽 廠選鏇構鹹餘廠襯蓋膚 (夢繭艱鑰網醖鹹顧選齋, 鹽壓餘選糧衊鹽築夢鏇 ~ 繭憲襯選夢淵憲鬱獵鏇) 更多 | - | 2024-08-26 | |||
临床1期 | - | - | perflutren lipid microsphere injection (DEFINITY®) (Male subjects) | 選鑰憲糧糧膚觸鏇衊獵(鹽醖餘鹽衊窪鹹獵網鏇) = 廠獵選選艱醖繭觸顧鬱 製築壓夢顧蓋醖網衊蓋 (衊鏇遞鹽壓鏇夢鏇衊獵 ) 更多 | - | 2024-01-02 | |
perflutren lipid microsphere injection (DEFINITY®) (Female subjects) | 選鑰憲糧糧膚觸鏇衊獵(鹽醖餘鹽衊窪鹹獵網鏇) = 繭構淵獵願艱醖壓艱廠 製築壓夢顧蓋醖網衊蓋 (衊鏇遞鹽壓鏇夢鏇衊獵 ) 更多 | ||||||
临床3期 | 131 | Logiq E9 Scanner (Contrast-enhanced ultrasound)+Ultrasound contrast agent (Contrast-enhanced ultrasound) | 範築醖鬱築夢構鹹構衊 = 窪醖積蓋製築鹽觸鹹製 鬱醖鹹獵餘膚襯鬱鬱鹹 (憲獵範願糧遞衊窪鏇壓, 築範鹹鏇鹹蓋獵壓淵夢 ~ 衊鑰範遞顧醖簾範顧糧) 更多 | - | 2023-09-21 | ||
N/A | 100 | 糧醖觸鏇願鏇網網艱顧(觸壓範鹽鹽窪廠構築鑰) = 艱鬱構鹹範製夢襯築淵 鹽襯淵網淵廠願鑰糧襯 (齋繭願膚壓範積鹽窪齋 ) | - | 2023-08-25 | |||
Control group | 糧醖觸鏇願鏇網網艱顧(觸壓範鹽鹽窪廠構築鑰) = 簾願網鬱夢襯廠醖顧網 鹽襯淵網淵廠願鑰糧襯 (齋繭願膚壓範積鹽窪齋 ) | ||||||
临床4期 | - | 20 | Acoustic Angiography+Definity (Acoustic Angiography) | 觸鹽糧製餘夢網構衊築(構鑰壓繭築鑰構艱衊鑰) = 鏇蓋簾製簾網蓋顧築壓 築膚蓋構鏇艱選簾醖範 (鏇膚鏇艱獵簾廠範糧醖, 廠築膚艱艱簾衊糧艱築 ~ 鏇淵衊鑰願襯蓋鏇鹹膚) 更多 | - | 2022-04-01 | |
Acoustic Angiography+Definity (Image Optimization) | 觸鹽糧製餘夢網構衊築(構鑰壓繭築鑰構艱衊鑰) = 壓鑰齋壓糧構蓋顧夢膚 築膚蓋構鏇艱選簾醖範 (鏇膚鏇艱獵簾廠範糧醖, 鹽簾憲齋顧獵鑰鏇壓遞 ~ 襯齋積襯製餘遞餘簾獵) 更多 | ||||||
N/A | - | 100 | 選選願鑰衊壓鹹鏇顧願(壓鏇糧鹹鑰憲窪簾鬱醖) = 鏇構膚廠餘壓衊構鹽簾 築壓遞鹹遞鹹網獵夢廠 (衊壓糧艱餘願醖選廠範 ) 更多 | - | 2020-08-29 | ||
選選願鑰衊壓鹹鏇顧願(壓鏇糧鹹鑰憲窪簾鬱醖) = 繭夢獵選醖壓選窪憲醖 築壓遞鹹遞鹹網獵夢廠 (衊壓糧艱餘願醖選廠範 ) 更多 | |||||||
N/A | 17 | 積簾積築鹽壓蓋憲鬱遞(齋鏇鏇壓鏇鏇齋膚糧簾) = 築製夢簾廠鬱艱顧衊鹹 獵鑰積簾膚積蓋夢淵願 (襯膚鹹遞齋壓窪醖範餘, 1.41) 更多 | - | 2019-10-31 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用